Breaking news from the prostate cancer front: the tiny imaging underdog with a radioactive name tag may have just saved a lot of men from an unnecessary biopsy.
The study is called PRIMARY2, and yes, that sounds like a robot sidekick from a low-budget space movie. But the idea is very human: if a man has a worrying prostate cancer risk signal, but his MRI looks normal or only mildly suspicious, does he really need a biopsy right away?
A biopsy is not a spa day. It is useful, often necessary, and occasionally life-saving. But it also involves needles, anxiety, infection risk, bleeding, and the charming experience of waiting for pathology results while your brain hosts a worst-case-scenario film festival.
PRIMARY2 asked whether a PSMA PET/CT scan could act like a better bouncer at the door.
The MRI Shrug Problem
Prostate cancer testing has gotten much smarter. PSA blood tests raise the alarm. MRI helps doctors see suspicious areas. Then biopsy confirms what is actually going on.
But sometimes MRI does the radiology equivalent of shrugging.
In this trial, men had either PI-RADS 2 findings, meaning not suspicious, but with high clinical risk, or PI-RADS 3 findings, meaning "could be something, could be nothing, please enjoy this diagnostic fog." These were biopsy-naive men, so nobody had yet taken tissue samples.
The old-school approach is: risk looks high, MRI is not fully reassuring, proceed to systematic transperineal biopsy. That can catch serious cancer, but it can also find slow, low-risk cancers that were minding their own business and may never hurt anyone. Cancer screening has this awkward talent for discovering trouble and non-trouble wearing similar hats.
Enter PSMA, the Scrappy Little Spotlight
PSMA stands for prostate-specific membrane antigen. It is a protein often found at higher levels on prostate cancer cells. A gallium-68 PSMA-11 PET/CT scan uses a radioactive tracer that binds to PSMA, making suspicious cells light up on imaging.
Think of it as giving prostate cancer cells glow-in-the-dark stickers, except the stickers are administered by nuclear medicine specialists and nobody is allowed to lick them.
In PRIMARY2, 660 men at seven Australian hospitals were randomly assigned to one of two paths: standard systematic transperineal biopsy, or [68Ga]Ga-PSMA-11 PET/CT first. If the PET/CT scan was positive, they had a targeted biopsy. If it was negative, they avoided biopsy.
That is the underdog move I love: not trying to replace everything, not barging in wearing sunglasses indoors, just asking, "What if we used the sharper flashlight before we start poking?"
The Part Where the Long Shot Scores
The PSMA PET/CT pathway found clinically significant prostate cancer at a rate that was non-inferior to standard biopsy: 12% in the PET/CT group versus 16% in the biopsy group. The difference was -3.7 percentage points, staying within the trial's non-inferiority margin.
Translation: the scan-first strategy did not appear to miss the meaningful cancers doctors were worried about.
Even better, 49% of men in the PSMA PET/CT group avoided biopsy within 6 months. That is not a rounding error. That is half the waiting room getting told, "You may not need the needle today," which is the kind of sentence that deserves its own small parade.
The scan-first approach also reduced detection of clinically insignificant prostate cancer, the low-risk stuff that can lead to overdiagnosis and overtreatment. That matters because finding cancer is not always the same as helping the patient. Sometimes the best medical move is to avoid turning a sleepy cellular oddball into a lifelong source of appointments, scans, and existential dread.
Why This Could Matter
If these findings hold up, PSMA PET/CT could help doctors sort men into better lanes after an unclear or reassuring MRI: biopsy for those with a concerning molecular signal, watchful restraint for those without one.
That could mean fewer unnecessary biopsies, fewer low-risk cancers being over-labeled, and more targeted sampling when biopsy is needed. For patients, it could mean less anxiety and fewer procedures. For clinicians, it could mean a cleaner diagnostic pathway instead of the current "MRI says maybe, PSA says panic, everyone grab a calendar" routine.
This also fits with earlier work. The original PRIMARY study found that adding PSMA PET/CT to MRI improved sensitivity and negative predictive value for clinically significant prostate cancer. Reviews and meta-analyses have also suggested that PSMA PET-targeted biopsy is promising, especially in tricky MRI categories like PI-RADS 3.
The Fine Print, Because Biology Always Reads the Contract
This is not a victory lap just yet. Follow-up is ongoing. The trial was done in Australia, where PSMA PET access is relatively strong, so cost and availability may look very different elsewhere. Health-economic analyses still matter, because scanners do not run on good vibes and academic enthusiasm. The authors also note that validation with other PSMA radiopharmaceuticals is needed.
And one limitation worth naming: ethnicity data were not collected. In prostate cancer, where risk and outcomes vary across populations, that gap matters.
Still, PRIMARY2 gives a very appealing possibility: a smarter middle step for men stuck between "MRI looks okay" and "your risk says we should not ignore this." It is not glamorous medicine. It is practical medicine. The kind that saves people from procedures they may not need while still chasing the cancers that can actually cause harm.
Underdog imaging test, take your modest bow.
References
-
Buteau JP, Moon D, Fahey MT, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. The Lancet Oncology. 2026. DOI: 10.1016/S1470-2045(26)00120-8
-
Emmett L, Buteau J, Papa N, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen PET-CT to Multiparametric MRI Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology. 2021;80(6):682-689. DOI: 10.1016/j.eururo.2021.08.002
-
Kawada T, Yanagisawa T, Rajwa P, et al. Diagnostic Performance of Prostate-specific Membrane Antigen PET-targeted Biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology. 2022;5(4):390-400. DOI: 10.1016/j.euo.2022.04.006
-
Cereser L, Evangelista L, Giannarini G, Girometti R. Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer. Diagnostics. 2023;13(16):2697. DOI: 10.3390/diagnostics13162697
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.